Precision BioSciences (DTIL) Competitors $4.26 +0.13 (+3.15%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$4.21 -0.05 (-1.17%) As of 07/2/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DTIL vs. DSGN, ESPR, NBTX, MDWD, CRDF, IMAB, PRQR, SOPH, SCPH, and MNPRShould you be buying Precision BioSciences stock or one of its competitors? The main competitors of Precision BioSciences include Design Therapeutics (DSGN), Esperion Therapeutics (ESPR), Nanobiotix (NBTX), MediWound (MDWD), Cardiff Oncology (CRDF), I-Mab (IMAB), ProQR Therapeutics (PRQR), SOPHiA GENETICS (SOPH), scPharmaceuticals (SCPH), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical products" industry. Precision BioSciences vs. Its Competitors Design Therapeutics Esperion Therapeutics Nanobiotix MediWound Cardiff Oncology I-Mab ProQR Therapeutics SOPHiA GENETICS scPharmaceuticals Monopar Therapeutics Design Therapeutics (NASDAQ:DSGN) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings. Which has preferable earnings and valuation, DSGN or DTIL? Precision BioSciences has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDesign TherapeuticsN/AN/A-$49.59M-$0.99-3.72Precision BioSciences$68.70M0.69$7.17M-$2.01-2.12 Does the media refer more to DSGN or DTIL? In the previous week, Precision BioSciences had 7 more articles in the media than Design Therapeutics. MarketBeat recorded 7 mentions for Precision BioSciences and 0 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 1.89 beat Precision BioSciences' score of 0.25 indicating that Design Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Design Therapeutics Very Positive Precision BioSciences Neutral Is DSGN or DTIL more profitable? Design Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -42.99%. Design Therapeutics' return on equity of -22.85% beat Precision BioSciences' return on equity.Company Net Margins Return on Equity Return on Assets Design TherapeuticsN/A -22.85% -22.02% Precision BioSciences -42.99%-69.26%-29.30% Do analysts rate DSGN or DTIL? Design Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 8.70%. Precision BioSciences has a consensus price target of $47.00, suggesting a potential upside of 1,003.29%. Given Precision BioSciences' stronger consensus rating and higher probable upside, analysts clearly believe Precision BioSciences is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Design Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of DSGN or DTIL? 56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 31.2% of Design Therapeutics shares are held by company insiders. Comparatively, 4.5% of Precision BioSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, DSGN or DTIL? Design Therapeutics has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. SummaryDesign Therapeutics beats Precision BioSciences on 8 of the 15 factors compared between the two stocks. Get Precision BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DTIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DTIL vs. The Competition Export to ExcelMetricPrecision BioSciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.79M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-2.1221.3126.1719.90Price / Sales0.69278.47413.55113.66Price / CashN/A41.4736.1356.90Price / Book0.627.518.025.38Net Income$7.17M-$55.05M$3.15B$248.50M7 Day Performance2.90%2.07%1.48%2.06%1 Month Performance-17.28%4.84%3.66%4.86%1 Year Performance-54.09%5.37%34.68%20.24% Precision BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DTILPrecision BioSciences4.5876 of 5 stars$4.26+3.1%$47.00+1,003.3%-54.7%$45.79M$68.70M-2.12200DSGNDesign Therapeutics0.7394 of 5 stars$3.90+4.3%$4.00+2.6%+15.0%$212.32MN/A-3.9440ESPREsperion Therapeutics4.1673 of 5 stars$1.04-2.8%$7.00+573.1%-50.9%$212.07M$332.31M-1.30200NBTXNanobiotix2.4603 of 5 stars$4.45-0.5%$8.00+79.8%-7.1%$210.68M-$11.61M0.00100Gap DownMDWDMediWound1.8364 of 5 stars$18.99-0.5%$31.80+67.5%+22.9%$206.32M$20.22M-9.0980News CoverageCRDFCardiff Oncology1.6866 of 5 stars$3.16+1.9%$12.00+279.7%+72.6%$206.23M$680K-3.4320IMABI-Mab3.0741 of 5 stars$2.46-1.6%$5.50+123.6%+44.9%$204.15M$3.89M0.00380News CoveragePRQRProQR Therapeutics2.1217 of 5 stars$1.95+1.0%$8.00+310.3%+29.5%$203.06M$20.46M-5.57180News CoverageSOPHSOPHiA GENETICS2.834 of 5 stars$3.05+0.3%$6.80+123.0%-33.8%$202.73M$65.17M-3.05520Positive NewsSCPHscPharmaceuticals4.6169 of 5 stars$3.83-0.3%$14.00+265.5%-4.0%$202.72M$36.33M-2.0130Positive NewsMNPRMonopar Therapeutics3.03 of 5 stars$31.83-3.1%$56.50+77.5%+876.7%$200.95MN/A-9.1510Positive NewsGap Up Related Companies and Tools Related Companies Design Therapeutics Alternatives Esperion Therapeutics Alternatives Nanobiotix Alternatives MediWound Alternatives Cardiff Oncology Alternatives I-Mab Alternatives ProQR Therapeutics Alternatives SOPHiA GENETICS Alternatives scPharmaceuticals Alternatives Monopar Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DTIL) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DTIL Stock Alerts